Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023
Eurosurveillance·
- DOI
- 10.2807/1560-7917.es.2024.29.38.2400575
- PMID
- 39301741
- PMCID
- PMC11484288
- OpenAlex
- W4402685088
- Study type
- Journal article
- Publisher
- European Centre for Disease Control and Prevention (ECDC)
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
The findings indicate that antibody responses to MVA-BN vaccination may not persist beyond one year, highlighting the need for ongoing surveillance to assess the public health implications of declining antibody levels for mpox outbreak preparedness.
Structured evidence summary
Research question
The study examined the persistence of orthopoxvirus-specific binding and MVA-neutralising antibodies one year after two-dose MVA-BN vaccination in at-risk individuals without prior smallpox or mpox vaccination.
Study design
The study followed at-risk individuals who received two subcutaneous doses of MVA-BN vaccine administered 4 weeks apart during the 2022-2023 mpox outbreak response in the Netherlands, measuring antibody levels at one year post-vaccination.
Population and setting
The study population consisted of at-risk individuals in the Netherlands who had not received prior smallpox or mpox vaccination and received MVA-BN vaccination between 2022 and 2023.
Main findings
Orthopoxvirus-specific binding antibodies and MVA-neutralising antibodies declined to undetectable levels one year following two-dose subcutaneous MVA-BN vaccination in previously unvaccinated at-risk individuals.
Public-health relevance
The findings indicate that antibody responses to MVA-BN vaccination may not persist beyond one year, highlighting the need for ongoing surveillance to assess the public health implications of declining antibody levels for mpox outbreak preparedness.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. Full interpretation of study limitations, including sample size, assay sensitivity thresholds, correlation between antibody levels and clinical protection, and generalizability to other dosing schedules or populations, requires access to the complete published article.
GIDS interpretation
The article is discoverable through mpox and smallpox disease classifiers and vaccination topic tags, providing context on immune response duration following outbreak-response vaccination. It does not report new case data or confirm an active surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.